Alliance for Clinical Trials in Oncology, shared on X:
“FDA approves new treatment option, atezolizumab in combination with chemotherapy, for patients with stage III dMMR colon cancer based on results from the phase III ATOMIC trial led by Alliance for Clinical Trials in Oncology.”
Learn more.
Frank Sinicrope, Clinical investigator of the Mayo Foundation, Co-leader GI Cancer Program at Mayo Clinic Rochester, added:
“Excited to report that FDA has approved atezolizumab + FP and oxali as adjuvant therapy for stage 3 dMMR colon cancer.
Important advance for patients worldwide.”
You may also be interested in:
FDA Approved Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer
